Histopathological examination coupled with immunohistochemistry (IHC) reveals the expression of key protein markers, such as HER2 in breast cancer or PD-L1 in non-small cell lung cancer, that directly inform the choice of targeted antibodies or immunotherapies [10]. This evidence concerns the gene ERBB2 and breast carcinoma.